Sarepta Therapeutics Inc

SRPT

$125.16

+71.2% last 12 months

Jim Simons Holding value: $101 Million Ken Griffin Holding value: $31.7 Million Steven Cohen Holding value: $6.06 Million Ray Dalio Holding value: $3.81 Million Ken Fisher Holding value: $1.56 Million Joel Greenblatt Holding value: $356 Thousand Mario Gabelli Holding value: $250 Thousand Ensemble Capital Holding value: $0 Tom Russo Holding value: $0 Cathie Wood Holding value: $0 Stanley Druckenmiller Holding value: $0 George Soros Holding value: $0

Market Cap

$11.6 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$61.28 - $159.89

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

-10.38x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $11.6 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $10.9 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $0.00 (0.0%)
1 Year Return Profit or loss of share price change plus dividend yield. +71.2%
52-Week High Highest share price in the last 52 weeks. $159.89
52-Week Low Lowest share price in the last 52 weeks. $61.28
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.0
Outstanding Shares The number of shares the company has issued and are held by stockholders. 93.1 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 2.17 Million

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. -10.38
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. -2.65
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. -$12.70
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 12.52
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 17.88
Enterprise Value to Revenue Enterprise value divided by revenue 11.2
Enterprise Value to EBIT Enterprise Value divided by EBIT -18.6
Total Debt to Enterprise Value Total debt divided by enterprise value 0.11
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 1.73

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $976 Million
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $832 Million
EBIT Earnings before tax and interest payments. -$587 Million
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. -$1.12 Billion
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. -114.30%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. +392.0%
Return on Equity Equity divided by market cap. -156.47%
Return on Assets Indicates a company's profitability in relation to its total assets. -36.45%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. -23.28%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q3 2022 Q4 2022 Q1 2023 Q2 2023

About Sarepta Therapeutics Inc

CEO: Douglas Ingram

Industry: Pharmaceutical Preparation Manufacturing

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of the end of 2019, the company has two approved drugs . Sarepta started in Corvallis, Oregon on January 1, 1980 and was originally named Antivirals Inc. After occupying several research laboratory spaces in Corvallis, the company opened a production laboratory in Corvallis in February 2002 and was renamed AVI BioPharma Inc. The company made headlines in 2003 when it announced work on treatments for severe acute respiratory syndrome and the West Nile virus. In July 2009, the company announced they would move their headquarters from Portland, Oregon, north to Bothell, Washington, near Seattle. At that time, the company led by president and CEO Leslie Hudson had 83 employees and quarterly revenues of $3.2 million. AVI had yet to turn a profit and had not yet developed any commercial products as of July 2009. The company lost $19.7 million in the second quarter of 2009, and then won an $11.5 million contract with the U.S. Department of Defense's Defense Threat Reduction Agency in October 2009. By this time, the company had completed its headquarters move to Bothell.

Similar stocks

Gilead Sciences, Inc.
Gilead Sciences, Inc.
Novavax, Inc.
Novavax, Inc.
Avidity Biosciences Inc
Avidity Biosciences Inc
Biocryst Pharmaceuticals Inc.
Biocryst Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
PTC Therapeutics Inc
PTC Therapeutics Inc
Insmed Inc
Insmed Inc

News

Scholar Rock extends slide amid concerns over Sarepta gene therapy approval

Scholar Rock extends slide amid concerns over Sarepta gene therapy approval

Scholar Rock (SRRK) slipped for the second straight session Thursday after the FDA delayed its decision on Sarepta''s (SRPT) gene therapy SRP-9001. Read more...

Seeking Alpha Seeking Alpha, 9 days ago
Why Shares of Sarepta Therapeutics Are Dropping Wednesday | The Motley Fool

Why Shares of Sarepta Therapeutics Are Dropping Wednesday | The Motley Fool

The FDA told the company that a review of a new therapy will take nearly a month longer.

Longport Longport, 10 days ago
Buy Sarepta Therapeutics For A Likely Positive FDA Decision Date

Buy Sarepta Therapeutics For A Likely Positive FDA Decision Date

SRP-9001’s pivotal trial surrogate endpoint was highly statistically significant. It will likely earn marketing authorization on May 29. See why SRPT stock i...

Seeking Alpha Seeking Alpha, 11 days ago
Argenx, Blueprint Medicines, Sarepta likely M&A targets - analyst

Argenx, Blueprint Medicines, Sarepta likely M&A targets - analyst

Argenx (ARGX) Blueprint Medicines (BPMC) and Sarepta Therapeutics (SRPT) are likely takeover targets in the biotech sector, according to a Wedbush analyst. A...

Seeking Alpha Seeking Alpha, 13 days ago
Never miss a trade
To improve your user experience we use cookies.